Want to see IN:TAKE full AI Analyst Report?
TAKE Stock Chart & Stats
₹40.52
₹0.00(0.00%)
At close: 4:00 PM EST
₹40.52
₹0.00(0.00%)
Day’s Range― - ―
52-Week Range₹8.83 - ₹49.90
Previous CloseN/A
Volume49.62K
Average Volume (3M)58.94K
Market Cap
₹3.21B
Enterprise Value₹4.33B
Total Cash (Recent Filing)₹186.41M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)28.2
Beta1.40
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.74
Shares Outstanding147,934,000
10 Day Avg. Volume129,011
30 Day Avg. Volume58,943
Financial Highlights & Ratios
PEG Ratio-0.75
Price to Book (P/B)18.74
Price to Sales (P/S)10.72
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Life-sciences Focused Software/servicesSpecialization in regulated life-sciences and supply-chain software/services creates durable demand and higher switching costs. TAKE’s work across implementation, validation and ongoing services supports recurring revenue, client stickiness, and long-term contracts typical in regulated industries.
Zero Reported DebtReported zero debt materially reduces financial risk and interest burden, improving flexibility to fund operations or strategic initiatives. This stronger leverage position supports resilience over the next several months and lowers near-term default or refinancing pressures.
Equity Recovered To PositiveRecovery of shareholders' equity after prior impairment restores balance-sheet buffer and credibility with counterparties. A positive equity base improves ability to absorb shocks, pursue contracts requiring financial stability, and support medium-term operational planning.
Bears Say
Negative Operating Cash FlowConsistent negative operating cash flow despite reported net income signals weak cash conversion and unreliable earnings quality. Over 2–6 months this undermines self-funded working capital, may force external financing or equity raises, and constrains investments in product and service delivery.
Negative Gross And Operating ProfitCore operations reported negative gross and operating profit in FY2026, indicating the business is not generating margin from its primary activities. Reliance on below-the-line items to report net income is not sustainable and raises structural concerns about long-term profitability.
High Earnings Volatility & Past ImpairmentHistorically volatile results and prior equity impairment signal unstable economics and uncertain forecasting. This variability complicates contract renewal negotiations, budgeting and capital allocation, and increases the likelihood of future financial stress or restructuring needs.
TAKE Solutions Limited News
TAKE FAQ
What was TAKE Solutions Limited’s price range in the past 12 months?
TAKE Solutions Limited lowest stock price was ₹8.83 and its highest was ₹49.90 in the past 12 months.
What is TAKE Solutions Limited’s market cap?
TAKE Solutions Limited’s market cap is ₹3.21B.
When is TAKE Solutions Limited’s upcoming earnings report date?
TAKE Solutions Limited’s upcoming earnings report date is Aug 12, 2026 which is in 27 days.
How were TAKE Solutions Limited’s earnings last quarter?
TAKE Solutions Limited released its earnings results on May 19, 2026. The company reported ₹0.29 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.29.
Is TAKE Solutions Limited overvalued?
According to Wall Street analysts TAKE Solutions Limited’s price is currently Overvalued.
Does TAKE Solutions Limited pay dividends?
TAKE Solutions Limited pays a Semiannually dividend of ₹0.4 which represents an annual dividend yield of N/A. See more information on TAKE Solutions Limited dividends here
What is TAKE Solutions Limited’s EPS estimate?
TAKE Solutions Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TAKE Solutions Limited have?
TAKE Solutions Limited has 147,934,000 shares outstanding.
What happened to TAKE Solutions Limited’s price movement after its last earnings report?
TAKE Solutions Limited reported an EPS of ₹0.29 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 4.961%.
Which hedge fund is a major shareholder of TAKE Solutions Limited?
Currently, no hedge funds are holding shares in IN:TAKE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TAKE Solutions Limited
TAKE Solutions Limited, operating across the United States, Asia Pacific, and Europe, specializes in providing expert services and cutting-edge solutions for the life sciences and supply chain management sectors. For the life sciences industry, the company delivers technology-driven and proprietary solutions, alongside consulting and practical services covering clinical trials, regulatory compliance, and patient safety. Its specific offerings in this area include clinical research, development of generic drugs, data analytics, regulatory affairs management, and pharmacovigilance. Beyond this, TAKE Solutions also offers IT infrastructure and support, comprehensive supply chain management, engineering, design, and sourcing services. The company caters to a diverse client base, encompassing both major and smaller innovative biopharmaceutical and medical device firms, as well as generic drug producers. Established in 2000, its main office is located in Chennai, India. TAKE Solutions Limited functions as a subsidiary of TAKE Solutions Pte. Limited.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Dishman Carbogen Amcis Ltd.
―
Syngene International Ltd.
―
OneSource Specialty Pharma Limited
―